🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "major milestone" in the effort against increasingly resistant strains of the infection, according to researchers.

A Worldwide Health Concern

Cases of gonorrhoea are increasing worldwide, with data suggesting over 82 million infections annually. Especially elevated rates are seen in the African continent and nations within the WHO's designated area, which encompasses China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely step in the reality of growing infection rates, escalating drug resistance and the highly restricted treatment choices at this time.”

Medical experts are increasingly worried about the rise in drug-resistant strains. The WHO has classified it as a "high-priority threat". Ongoing monitoring showed that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Drugs Receive Approval

One new antibiotic, marketed under the name a brand name, was approved by the American regulatory agency in December for treating gonorrhoea. This disease can lead to serious health problems, including infertility. Researchers hope that targeted use of this new drug will help delay the emergence of superbugs.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, also received approval in concurrent days. This medication, which is employed against urinary tract infections, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Partnership

This new treatment stemmed from a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to develop it.

“This milestone signifies a significant shift in the management of highly resistant gonorrhoea, which previously has been outpacing medical innovation.”

Clinical Trial Results and Global Access

Based on data published in a major medical journal, the new drug cured over nine in ten of genital gonorrhoea infections. This establishes an comparable level with the typical regimen, which uses a dual-drug approach. The trial involved nearly 1,000 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, GARDP has the rights to register and commercialise the drug in numerous regions with limited resources.

Medical professionals treating patients have shared positive views. Having a single-dose, oral treatment such as this is described as a "critical tool" for gonorrhoea control. This is viewed as crucial to lessen the impact of the illness for individuals and to halt the transmission of extremely resistant gonorrhoea around the world.